Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/103711
Title: Levels of serum brain-derived neurotropic factor in individuals at ultra-high risk for psychosis—findings from the longitudinal youth at risk study (LYRIKS)
Authors: Lee, Jimmy
Yee, Jie Yin
Lee, Tih-Shih
Keywords: DRNTU::Science::Medicine
Brain-derived Neurotrophic Factor
Ultra-high Risk Of Psychosis
Issue Date: 2018
Source: Yee, J. Y., Lee, T.-S., & Lee, J. (2018). Levels of Serum Brain-Derived Neurotropic Factor in Individuals at Ultra-High Risk for Psychosis—Findings from the Longitudinal Youth at Risk Study (LYRIKS). International Journal of Neuropsychopharmacology, 21(8), 734-739. doi:10.1093/ijnp/pyy036
Series/Report no.: International Journal of Neuropsychopharmacology
Abstract: Background:Identifying biomarkers to enrich prognostication and risk predictions in individuals at high risk of developing psychosis will enable stratified early intervention efforts. Brain-derived neurotrophic factor has been widely studied in schizophrenia and in first-episode psychosis with promising results. The aim of this study was to examine the levels of serum brain-derived neurotrophic factor between healthy controls and individuals with ultra-high risk of psychosis.Methods:A sample of 106 healthy controls and 105 ultra-high risk of psychosis individuals from the Longitudinal Youth at Risk Study was included in this study. Ultra-high risk of psychosis status was determined using the Comprehensive Assessment of At-Risk Mental State at recruitment. Calgary Depression Scale for Schizophrenia was used to assess the severity of depression. All participants were followed up for 2 years, and ultra-high risk of psychosis remitters were defined by ultra-high risk of psychosis individuals who no longer fulfilled Comprehensive Assessment of At-Risk Mental State criteria at the end of the study period. Levels of brain-derived neurotrophic factor were measured in the serum by enzyme-linked immunosorbent assay method.Results:The ultra-high risk of psychosis group had significantly higher baseline levels of serum brain-derived neurotrophic factor compared with the control group (3.7 vs 3.3 ng/mL, P=.018). However, baseline levels of serum brain-derived neurotrophic factor did not predict the development of psychosis (OR=0.64, CI=0.40–1.02) or remission (OR=0.83, CI=0.60–1.15) from ultra-high risk of psychosis status.Conclusion:Findings from our study did not support a role for serum brain-derived neurotrophic factor in predicting outcomes in ultra-high risk of psychosis individuals. However, the finding of higher levels of serum brain-derived neurotrophic factor in ultra-high risk of psychosis individuals deserves further study.
URI: https://hdl.handle.net/10356/103711
http://hdl.handle.net/10220/47370
ISSN: 1461-1457
DOI: 10.1093/ijnp/pyy036
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
Rights: © 2018 The Author(s). Published by Oxford University Press on behalf of CINP. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
Levels of Serum Brain-Derived Neurotropic Factor in.pdf411.99 kBAdobe PDFThumbnail
View/Open

SCOPUSTM   
Citations 20

12
Updated on Mar 18, 2025

Web of ScienceTM
Citations 20

9
Updated on Oct 25, 2023

Page view(s)

363
Updated on Mar 19, 2025

Download(s) 50

90
Updated on Mar 19, 2025

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.